Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650401 · ClinicalTrials.gov registry record · Phase 1
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
A Phase 1 study of Solid Tumors and CNS Tumors, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT02650401: Active Phase 1 study of Solid Tumors and CNS Tumors, sponsored by Hoffmann-La Roche.
NCT02650401 is a Phase 1 study of Solid Tumors and CNS Tumors that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 69 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02650401, a Phase 1 study of Solid Tumors and CNS Tumors, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Primary Outcome
Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03)
Conditions Studied
Interventions
- DRUG Entrectinib
Study Locations (20)
Other
- Beijing Children's Hospital, Capital Medical University - Beijing
- Centre Leon Berard - Lyon
- Hôpital de la Timone, Oncologie Pédiatrique - Marseille
California
- University of California San Diego - La Jolla
- UCSF Benioff Children's Hospital - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Egleston Children's Hospital at Emory University Atlanta - Atlanta
Illinois
- University of Chicago - Chicago
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University,St. Louis Children's Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2016-05-03 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
What the registry record for NCT02650401 still lists
NCT02650401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Entrectinib is the first listed.
NCT02650401 names 20 study sites across 17 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02650401 about?
NCT02650401 is a clinical study titled "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options". This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid...
What is the current status of trial NCT02650401?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2016-05-03. Estimated completion is 2026-06-30.
What conditions does trial NCT02650401 study?
This clinical trial studies the following conditions: Solid Tumors, CNS Tumors.
What interventions are being tested in trial NCT02650401?
The interventions under investigation include: Entrectinib (DRUG).
Who is sponsoring clinical trial NCT02650401?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02650401 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02650401's enrollment target sits among peer trials
69 64th of 125 higher than 62 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI